Allergen immunotherapy: A practice parameter

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 1 SUPPL. 1, 2003, Pages 1-40

  Li, James T ^a   Lockey, Richard F ^a   Bernstein, I Leonard ^a   Portnoy, Jay M ^a   Nicklas, Richard A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5 ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROSS ALLERGY; CROSS REACTION; DESENSITIZATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOMODULATION; IMMUNOTHERAPY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SKIN TEST; TREATMENT OUTCOME; VACCINATION;

EID: 0012715074     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63600-9     Document Type: Review

References (210)

1. Practice parameters for allergen immunotherapy. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1996;98:1001-1011.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-596.
3. WHO Position Paper: allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl):1-42.
4. Lockey RF. How now, brown cow, vaccine or extract? Curr Allergy Asthma Rep 2002;2:181-182.
5. Bernstein IL, Storms WW. Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1995;75:543-625.
6. Practice parameters for the diagnosis and treatment of asthma. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1995;96:707-870.
7. Li JT, Pearlman DS, Nicklas RA, et al. Algorithm for the diagnosis and management of asthma: a practice parameter update. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:415-420.
8. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518.
9. Portnoy JM, Moffitt JE, Golden DB, et al. Stinging insect hypersensitivity: a practice parameter. The Joint Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1999;103:963-980.
10. The diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998;101:S465-S528.
11. Kao N. Terminology used for allergen immunotherapy. Ann Allergy Asthma Immunol 2000;84:273-274.
12. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572.
13. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911;2:814-817.
14. Akdis CA, Blaser K. Immunologic mechanisms of specific immunotherapy. Allergy 1999;54(Suppl):31-32. (LB)
15. Bellinghausen I, Metz G, Enk AH, et al. Insect venom immunotherapy induces interleukin-10 production and a Th2- to Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139. (LB)
16. Marcotte GV, Braun CM, Norman PS, et al. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998;101:506-513. (LB)
17. Akdis CA, Blesken T, Wymann D, et al. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914-925. (LB)
18. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-260. (IIb)
19. Verheyen J, Bonig H, Kim YM, et al. Regulation of interleukin-2 induced interleukin-5 and interleukin-13 production in human peripheral blood mononuclear cells. Scand J Immunol 2000;51:45-53. (IIb)
20. Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 2000;84:241-243. (IIb)
21. Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest 1976;57:1378-1385. (IIa)
22. Secrist H, Chelen CJ, Wen Y, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30. (IIa)
23. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen - stimulated T cell cultures. J Immunol 1995;154:4187-4194. (IIb)
24. Müller U, Akdis CA, Fricker M, et al. Successful immuno-therapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-754. (IIa)
25. Gaglani B, Borish L, Bartelson BL, et al. Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:259-265. (IIa)
26. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.) (LB)
27. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999;13:603-609. (IIb)
28. Larche M. Changes in interferon-γ production following specific allergen immunotherapy: biology vs methodology. Clin Exp Allergy 2000;30:297-300. (IIb)
29. Bousquet J, Braquemond P, Feinberg J, et al. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy 1986;56:456-459. (IIa)
30. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70:261-271. (IIa)
31. Sadan N, Rhyne MB, Mellits ED, et al. Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med 1969;280:623-627. (IIa)
32. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-651. (IIb)
33. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest 1985;76:2247-2253. (IIa)
34. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:470-480. (IIb)
35. Ebner C. Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 1999;119:1-5. (III)
36. Bousquet J, Maasch H, Martinot B, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-446. (Ib)
37. Peng ZK, Naclerio RM, Norman PS, Adkinson NF Jr. Quantitative IgE- and IgG-subclass responses during and after longterm ragweed immunotherapy. J Allergy Clin Immunol 1992;89:519-529. (IIb)
38. Lockey RF. "ARIA": global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001;108:497-499. (IV)
39. Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000;106:41-45. (IIb)
40. The use of standardized allergen extracts: American Academy of Allergy, Asthma and Immunology (AAAAI). J Allergy Clin Immunol 1997;99:583-586. (IIb)
41. Baer H, Godfrey H, Maloney CJ, et al. The potency and antigen E content of commercially prepared ragweed extracts. J Allergy 1970;45:347-354. (IIb)
42. Greenert S, Bernstein IL, Michael JG. Immune responses of non-atopic individuals to prolonged immunisation with ragweed extract. Lancet 1971;2:1121-1123. (IIb)
43. Baer H, Maloney CJ, Norman PS, Marsh DG. The potency and Group I antigen content of six commercially prepared grass pollen extracts. J Allergy Clin Immunol 1974;54:157-164. (IIb)
44. Leiferman KM, Gleich GJ. The cross-reactivity of IgE anti-bodies with pollen allergens. I. Analyses of various species of grass pollens. J Allergy Clin Immunol 1976;58:129-139. (LB)
45. Martin BG, Mansfield LE, Nelson HS. Cross-allergenicity among the grasses. Ann Allergy 1985;54:99-104. (LB)
46. van Ree R, van Leeuwen WA, Aalberse RC. How far can we simplify in vitro diagnostics for grass pollen allergy? A study with 17 whole pollen extracts and purified natural and recombinant major allergens. J Allergy Clin Immunol 1998;102:184-190. (LB)
47. Karl S, Rakoski J. Hyposensitization with cross-reacting pollen allergens [in German]. Z Hautkr 1988;63(Suppl):55-57. (III)
48. Bernstein IL, Perera M, Gallagher J, et al. In vitro cross-allergenicity of major aeroallergenic pollens by the radioaller-gosorbent technique. J Allergy Clin Immunol 1976;57:141-152. (LB)
49. Gonzalez RM, Cortes C, Conde J, et al. Cross-reactivity among five major pollen allergens. Ann Allergy 1987;59:149-154. (LB)
50. Fahlbusch B, Muller WD, Rudeschko O, et al. Detection and quantification of group 4 allergens in grass pollen extracts using monoclonal antibodies. Clin Exp Allergy 1998;28:799-807. (LB)
51. Lowenstein H. Timothy pollen allergens. Allergy 1980;35:188-191. (LB)
52. Leavengood DC, Renard RL, Martin BG, Nelson HS. Cross allergenicity among grasses determined by tissue threshold changes. J Allergy Clin Immunol 1985;76:789-794. (III)
53. Phillips JW, Bucholtz GA, Fernandez-Caldas E, et al. Bahia grass pollen, a significant aeroallergen: evidence for the lack of clinical cross-reactivity with timothy grass pollen. Ann Allergy 1989;63:503-507. (III)
54. Yoo TJ, Spitz E, McGerity JL. Conifer pollen allergy: studies of immunogenicity and cross antigenicity of conifer pollens in rabbit and man. Ann Allergy 1975;34:87-93. (III)
55. Black JH. Cedar hay fever. J Allergy 1929;1:71-73. (III)
56. Pham NH, Baldo BA, Bass DJ. Cypress pollen allergy: identification of allergens and crossreactivity between divergent species. Clin Exp Allergy 1994;24:558-565. (LB)
57. Barletta B, Affemi C, Tinghino R, et al. Cross-reactivity between Cupressus arizonica and Cupressus sempervirens pollen extracts. J Allergy Clin Immunol 1996;98:797-804. (LB)
58. Weber RW. Cross-reactivity among pollens. Ann Allergy 1981;46:208-215. (III)
59. Lowenstein H. Cross reactions among pollen antigens. Allergy 1980;35:198-200. (LB)
60. Zetterstrom O, Fagerberg E, Wide L. An investigation of pollen extracts from different deciduous trees in patients with springtime allergy in Sweden. Acta Allergol 1972;27:15-21. (III)
61. Serafina U. Studies on hay fever, with special regard to pollinosis due to Parietaria officinalis. Acta Allergol Kbh 1957;11:3-27. (III)
62. Holgate ST, Jackson L, Watson HK, Ganderton MA. Sensitivity to Parietaria pollen in the Southampton area as determined by skin-prick and RAST tests. Clin Allergy 1988;18:549-556. (III)
63. Eriksson NE. Allergy to pollen from different deciduous trees in Sweden: an investigation with skin tests, provocation tests and the radioallergosorbent test (RAST) in springtime hay fever patients. Allergy 1978;33:299-309. (III)
64. Bousquet J, Guerin B, Hewitt B, et al. Allergy in the Mediterranean area. III: Cross reactivity among Oleaceae pollens. Clin Allergy 1985;15:439-448. (LB)
65. Kernerman SM, McCullough J, Green J, Ownby DR. Evidence of cross-reactivity between olive, ash, privet, and Russian olive tree pollen allergens. Ann Allergy 1992;69:493-496. (III)
66. Yunginger JW, Gleich GJ. Measurement of ragweed antigen E by double antibody radioimmunoassay. J Allergy Clin Immunol 1972;50:326-337. (LB)
67. Leiferman KM, Gleich GJ, Jones RT. The cross-reactivity of IgE antibodies with pollen allergens. II. Analyses of various species of ragweed and other fall weed pollens. J Allergy Clin Immunol 1976;58:140-148. (LB)
68. Katial RK, Lin FL, Stafford WW, et al. Mugwort and sage (Artemisia) pollen cross-reactivity: ELISA inhibition and immunoblot evaluation. Ann Allergy Asthma Immunol 1997;79:340-346. (LB)
69. Weber RW, Nelson HS. Chenopod-Amaranth cross-allergenicity: evaluated by RAST inhibition. Ann Allergy 1984;52:226. (III)
70. Weber RW. Cross-reactivity among Chenopod-Amaranth weeds: skin test correlation. Ann Allergy 1987;58:287. (LB)
71. Helm RM, Squillace DL, Jones RT, Brenner RJ. Shared allergenic activity in Asian (Blattella asahinai), German (Blattella germanica), American (Periplaneta americana), and Oriental (Blatta orientalis) cockroach species. Int Arch Allergy Appl Immunol 1990;92:154-161. (LB)
72. Freeman TM, Hylander R, Ortiz A, Martin ME. Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol 1992;90:210-215. (IIa)
73. Triplett RF. Sensitivity to the imported fire ant: successful treatment with immunotherapy. South Med J 1973;66:477-480. (III)
74. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-974. (Ia)
75. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000;22:329-341. (Ia)
76. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther 2000;22:342-350. (Ia)
77. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000;22:351-358. (Ia)
78. Portnoy JM. Immunotherapy for asthma: unfavorable studies. Ann Allergy Asthma Immunol 2001;87(Suppl):28-32.
79. Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965;273:675-679.
80. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001;56:301-306.
81. Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-161. (IIa)
82. Bousquet J, Muller UR, Dreborg S, et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987;42:401-413. (III)
83. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children - a 14-year study. Pediatrics 1968;42:793-802. (Ib)
84. Cantani A, Arcese G, Lucenti P, et al. A three-year prospective study of specific immunotherapy to inhalant allergens: evidence of safety and efficacy in 300 children with allergic asthma. J Investig Allergol Clin Immunol 1997;7:90-97.
85. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-331. (Ib)
86. Hedlin G, Wille S, Browaldh L, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999;103:609-614. (Ib)
87. Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or both house-dust mite and grass pollen. Allergy 2000;55:69-73.
88. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-453. (III)
89. Ohashi Y, Nakai Y, Tanaka A, et al. Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg 1998;124:1337-1346. (III)
90. Portnoy JM. Immunotherapy for allergic diseases. Clin Rev Allergy Immunol 2001;21:241-259.
91. Cantani A, Micera M. Is specific immunotherapy safe and effective in children? Eur Rev Med Pharmacol Sci 2000;4:139-143.
92. Norman PS, Winkenwerder WL, Lichtenstein LM. Immuno-therapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. J Allergy 1968;42:93-108.
93. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:43-53. (IIb)
94. Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Doubleblind, placebo-controlled immunotherapy with mixed grasspollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-598. (Ib)
95. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489-500. (Ib)
96. Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy 1994;49:13-21. (Ib)
97. Creticos PS, Marsh DG, Proud D, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989;84:197-205.
98. Ariano R, Kroon AM, Augeri G, et al. Long-term treatment with allergoid immunotherapy with Parietaria: clinical and immunologic effects in a randomized, controlled trial. Allergy 1999;54:313-319. (Ib)
99. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-506. (Ib)
100. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475. (Ib)
101. Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 1986;41:131-140. (Ib)
102. Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebocontrolled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-472. (IIa)
103. Malling HJ. Diagnosis and immunotherapy of mould allergy. IV. Relation between asthma symptoms, spore counts and diagnostic tests. Allergy 1986;41:342-350. (IIa)
104. Karlsson R, Agrell B, Dreborg S, et al. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. II. In vitro results. Allergy 1986;41:141-150. (Ib)
105. Mailing HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:507-519.
106. Malling HJ, Djurup R. Diagnosis and immunotherapy of mould allergy. VII. IgG subclass response and relation to the clinical efficacy of immunotherapy with Cladosporium. Allergy 1988;43:60-70.
107. Bertelsen A, Andersen JB, Christensen J, et al. Immunotherapy with dog and cat extracts in children. Allergy 1989;44:330-335.
108. Haugaard L, Dahl R. Immunotherapy in patients allergic to cat and dog dander. I. Clinical results. Allergy 1992;47:249-254.
109. Ohman JL Jr, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma: double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984;74:230-239. (Ib)
110. Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind, placebo-controlled trial. Clin Exp Allergy 1997;27:860-867. (Ib)
111. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93:556-566. (Ib)
112. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991;87:955-964. (IIa)
113. Aas K. Hyposensitization in house dust allergy asthma: a double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust. Acta Paediatr Scand 1971;60:264-268. (Ib)
114. Pauli G, Bessot JC, Bigot H, et al. Clinical and immunologic evaluation of tyrosine-adsorbed Dermatophagoides pteronyssinus extract: a double-blind placebo-controlled trial. J Allergy Clin Immunol 1984;74:524-535. (Ib)
115. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:971-977.
116. Bonno M, Fujisawa T, Iguchi K, et al. Mite-specific induction of interleukin-2 receptor on T lymphocytes from children with mite-sensitive asthma: modified immune response with immunotherapy. J Allergy Clin Immunol 1996;97:680-688.
117. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-722. (Ib)
118. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985;76:734-744.
119. Olsen OT, Larsen KR, Jacobsen L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997;52:853-859. (Ib)
120. Pichler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274-283.
121. McHugh SM, Lavelle B, Kemeny DM, et al. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:521-531. (Ib)
122. Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. J Asthma 1988;25:205-218. (IIb)
123. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-433.
124. Jacobsen L, Nuchel Petersen B, Wihl JA, et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52:914-920.
125. Moller C, Dreborg S, Ferduosi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-256. (Ib)
126. Jacobsen L. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol 2001;87:43-46.
127. Sampson HA. Food anaphylaxis. Br Med Bull 2000;56:925-935.
128. Rance F. Current childhood food allergies [in French]. Allerg Immunol 2000;32:366-376.
129. Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997;99:744-751. (IIa)
130. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001;124:70-72. (LB)
131. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-446. (Ib)
132. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87:47-55. (III)
133. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323-332.
134. Greenberg MA, Kaufman CR, Gonzalez GE, et al. Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986;77:865-870. (III)
135. Matloff SM, Bailit IW, Parks P, et al. Systemic reactions to immunotherapy. Allergy Proc 1993;14;347-350. (IV)
136. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-677. (III)
137. Javeed N, Javeed H, Javeed S, et al. Refractory anaphylactoid shock potentiated by β-blockers. Cathet Cardiovasc Diagn 1996;39:383-384. (IV)
138. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on β-adrenergic blockers or with asthma. Ann Intern Med 1991;115:270-276. (III)
139. Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both β-blocker exposure and cardiovascular disorders. Arch Intern Med 1993;153:2033-2040. (III)
140. Kivity S, Yarchovsky J. Relapsing anaphylaxis to bee sting in a patient treated with β-blocker and Ca blocker. J Allergy Clin Immunol 1990;85:669-670. (IV)
141. Toogood JH. Risk of anaphylaxis in patients receiving β-blocker drugs. J Allergy Clin Immunol 1988;81:1-5. (IV)
142. Bickell WH, Dice WH. Military antishock trousers in a patient with adrenergic-resistant anaphylaxis. Ann Emerg Med 1984;13:189-190. (IV)
143. Jacobs RL, Rake GW Jr, Fournier DC, et al. Potentiated anaphylaxis in patients with drug-induced β-adrenergic blockade. J Allergy Clin Immunol 1981;68:125-127. (IV)
144. Newman BR, Schultz LK. Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride. Ann Allergy 1981;47:35-37. (IV)
145. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30:1144-1150. (III)
146. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998;101:33-37. (III)
147. Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics 2000;106:1040-1044. (III)
148. Simons FE, Gu X, Simons KJ. Outdated EpiPen and EpiPen Jr autoinjectors: past their prime? J Allergy Clin Immunol 2000;105:1025-1030.
149. Personnel and equipment to treat systemic reactions caused by immunotherapy with allergenic extracts: American Academy of Allergy and Immunology. J Allergy Clin Immunol 1986;77:271-273. (IV)
150. Bousquet J, Hejjaoui A, Dhivert H, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797-802. (IIa)
151. Duplantier JE, Freeman TM, Bahna SL, et al. Successful rush immunotherapy for anaphylaxis to imported fire ants. J Allergy Clin Immunol 1998;101:855-856.
152. Golden DB, Kagey-Sobotka A, Norman PS, et al. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001;107:897-901. (III)
153. Reisman RE. Insect sting allergy: the dilemma of the negative skin test reactor. J Allergy Clin Immunol 2001;107:781-782. (IV)
154. van der Zee JS, de Groot H, van Swieten P, et al. Discrepancies between the skin test and IgE antibody assays: study of histamine release, complement activation in vitro, and occurrence of allergen-specific IgG. J Allergy Clin Immunol 1988;82:270-281.
155. Bryant DH, Burns MW, Lazarus L. The correlation between skin tests, bronchial provocation tests and the serum level of IgE specific for common allergens in patients with asthma. Clin Allergy 1975;5:145-157. (IIa)
156. Berg TL, Johansson SG. Allergy diagnosis with the radioallergosorbent test: a comparison with the results of skin and provocation tests in an unselected group of children with asthma and hay fever. J Allergy Clin Immunol 1974;54:209-221.
157. Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J Allergy Clin Immunol 1999;103:773-779. (IIb)
158. Vailes L, Sridhara S, Cromwell O, et al. Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products. J Allergy Clin Immunol 2001;107:641-646. (LB)
159. Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996;98:382-388. (III)
160. Kordash TR, Amend MJ, Williamson SL, et al. Effect of mixing allergenic extracts containing Helminthosporium, D. farinae, and cockroach with perennial ryegrass. Ann Allergy 1993;71:240-246. (III)
161. Nolte H. Optimal maintenance dose immunotherapy based on major allergen content or potency labeling. Allergy 1998;53:99-100.
162. Van Metre TE Jr, Adkinson NF Jr, Lichtenstein LM, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:288-297. (IIa)
163. Grobe K, Becker WM, Schlaak M, Petersen A. Grass group I allergens (β-expansins) are novel, papain-related proteinases. Eur J Biochem 1999;263:33-40.
164. Nelson HS. Effect of preservatives and conditions of storage on the potency of allergy extracts. J Allergy Clin Immunol 1981;67:64-69. (LB)
165. Anderson MC, Baer H. Antigenic and allergenic changes during storage of a pollen extract. J Allergy Clin Immunol 1982;69:3-10. (III)
166. Bonifazi F, Bilo MB. Efficacy of specific immunotherapy in allergic asthma: myth or reality? Allergy 1997;52:698-710.
167. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000;106:840-843.
168. Kinkade S. Do patients with local reactions to allergy shots require dosage reductions for subsequent injections? J Fam Pract 2001;50:202.
169. Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69:181-193. (III)
170. Taber AI, Muro MD, Garcia BE, et al. Dermatophagoides pteronyssinus cluster immunotherapy: a controlled trial of safety and clinical efficacy. J Investig Allergol Clin Immunol 1999;9:155-164. (Ib)
171. Miller DL, Mansmann HC Jr. Rapid injection therapy in children with intractable asthma: safety and technique. Ann Allergy 1971;29:178-186. (III)
172. Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol 1996;76:175-180. (III)
173. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994;73:423-428.
174. Hejjaoui A, Ferrando R, Dhivert H, et al. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992;89:925-933. (III)
175. Westall GP, Thien FC, Czarny D, et al. Adverse events associated with rush Hymenoptera venom immunotherapy. Med J Aust 2001;174:227-230.
176. Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy 1992;68:493-498. (III)
177. Portnoy J, Bagstad K, Kanarek H, et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994;73:409-418. (IIb)
178. Tankersley MS, Walker RL, Butler WK, et al. Safety and efficacy of an imported fire and rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002;109:556-562.
179. Position statement on the administration of immunotherapy outside of the prescribing allergist facility. Drugs and Anaphylaxis Committee of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:101-102. (IV)
180. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to the house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001;31:1392-1397.
181. La Rosa M, Ranno C, Andre C, et al. Double-blind placebocontrolled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425-432. (IIa)
182. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999;104:964-968. (IIa)
183. Purello-D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999;54:968-973. (IIa)
184. Passalacqua G, Bagnasco M, Mariani G, et al. Local immunotherapy: pharmacokinetics and efficacy. Allergy 1998;53:477-484. (IIb)
185. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100:122-129. (IIb)
186. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:229-236. (IIa)
187. Pajno GB, Morabito L, Barberio G, et al. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebocontrolled study. Allergy 2000;55:842-849. (Ib)
188. Marcucci F, Sensi L, Frati F, et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001;56:1091-1095.
189. Bjorksten B, Moller C, Broberger U, et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 1986;41:290-295. (IIa)
190. Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 1997;100:30-38.
191. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:61-67. (IIb)
192. Georgitis JW, Clayton WF, Wypych JI, et al. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol 1984;74:694-700.
193. D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995;25:141-148. (Ib)
194. Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;25:1092-1099. (Ib)
195. Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am J Respir Crit Care Med 1995;152:461-466. (IIa)
196. Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria: a double-blind controlled study. Allergy 1992;47:318-323. (Ib)
197. Andri L, Senna G, Betteli C, et al. Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 1993;91:987-996. (Ib)
198. Passalacqua G, Albano M, Pronzato C, et al. Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy 1997;27:904-908. (IIb)
199. Machiels JJ, Somville MA, Lebrun PM, et al. Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergenantibody complexes. J Clin Invest 1990;85:1024-1035.
200. Spiegelberg HL, Orozco EM, Roman M, Raz E. DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy 1997;52:964-970.
201. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141-5145.
202. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-134.
203. Jilek S, Barbey C, Spertini F, Corthesy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice. J Immunol 2001;166:3612-3621.
204. Kumar M, Behera AK, Hu J, et al. IFN-γ and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy, J Allergy Clin Immunol 2001;108:402-408.
205. Kreig AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998;6:23-27.
206. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody: rhuMAb-E25 Study Group. N Engl J Med 1999;341:1966-1973.
207. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-259.
208. Foster PS, Hogan SP, Ramsay AJ, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996;183:195-201.
209. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
210. Izuhara K, Yanagihara Y, Hamaasaki N, et al. Atopy and the human IL-4 receptor α chain. J Allergy Clin Immunol 2000;106:S65-S71.